Try our beta test site

Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00365716
First received: August 16, 2006
Last updated: October 6, 2015
Last verified: October 2015
Results First Received: May 19, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Prevention
Conditions: Papillomavirus Infections
Genital Diseases, Female
Interventions: Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20
Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40
Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80
Biological: Placebo (mcg) (Aluminum Adjuvant)225
Biological: Placebo (mcg) (Aluminum Adjuvant) 450

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20

The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.

The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36.

Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40

The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.

The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36.

Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80

The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.

The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36.

Placebo (mcg) (Aluminum Adjuvant) 225

The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.

The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36.

Placebo (mcg) (Aluminum Adjuvant) 450

The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.

The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36.

Total Total of all reporting groups

Baseline Measures
   Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20   Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40   Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80   Placebo (mcg) (Aluminum Adjuvant) 225   Placebo (mcg) (Aluminum Adjuvant) 450   Total 
Overall Participants Analyzed 
[Units: Participants]
 290   284   292   146   146   1158 
Age 
[Units: Years]
Mean (Full Range)
 20.2 
 (16 to 23) 
 20.0 
 (15 to 24) 
 20.1 
 (16 to 23) 
 20.0 
 (16 to 23) 
 20.1 
 (13 to 23) 
 20.0 
 (13 to 24) 
Gender 
[Units: Participants]
           
Female   290   284   292   146   146   1158 
Male   0   0   0   0   0   0 
Race/Ethnicity, Customized 
[Units: Participants]
           
Asian   7   11   5   6   5   34 
Black   25   32   27   12   7   103 
Hispanic American   15   15   10   10   11   61 
Indian   0   0   2   0   0   2 
Multi-racial   13   9   6   7   4   39 
Native American   2   4   2   0   1   9 
White   228   213   240   111   118   910 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Subjects With Injection Site Adverse Experiences   [ Time Frame: Days 1-5 following any vaccination visit ]

2.  Secondary:   Incidence of HPV 6-, 11-, 16- or 18-related Persistent Infection or Disease (Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Adenocarcinoma in Situ, Cervical Cancer, and Genital Warts)   [ Time Frame: Through 36 Months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information